NCT04100330View on ClinicalTrials.gov

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2020

Primary Completion Date

March 27, 2020

Study Completion Date

March 27, 2020

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Ficlatuzumab

Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.

DRUG

Cytarabine

Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.

Sponsors

Collaborators (1)

Biodesix, Inc.
All Listed Sponsors
collaborator

Biodesix, Inc.

INDUSTRY

lead

AVEO Pharmaceuticals, Inc.

INDUSTRY